search
Back to results

Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients

Primary Purpose

Pressure Ulcer

Status
Recruiting
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
alanyl-glutamine
Sponsored by
Air Force Specialized Hospital, Cairo, Egypt
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pressure Ulcer

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with pressure ulcers stage 2,3 or 4, non-healing admitted to Air force specialized hospital for more than a week.

Exclusion Criteria:

  • Patients with renal impairment (GFR </= 30)
  • Patients who require fluid restriction < 1 Litre/day.
  • Patients with liver cirrhosis. (Child B and C)
  • Length of stay< 2 weeks.
  • Patients with deep tissue infection and/or requiring debridement of necrotic or sloughy tissue.
  • Hemodynamically unstable patients. (On high dose of cardiac supports)

Sites / Locations

  • Air Force Specialized HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

control group

alanyl-glutamine group

Arm Description

100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations

100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration).

Outcomes

Primary Outcome Measures

Percentage change in pressure ulcer length
Final ulcer length/original ulcer length x 100
Percentage change in pressure ulcer depth
Final ulcer depth/original ulcer depth x 100
Percentage change in pressure ulcer area
Final ulcer area/original ulcer area x 100
Percentage change in proportion of viable wound tissue
Final proportion of viable wound tissue /original proportion of viable wound tissue x 100

Secondary Outcome Measures

Full Information

First Posted
October 15, 2022
Last Updated
October 15, 2022
Sponsor
Air Force Specialized Hospital, Cairo, Egypt
search

1. Study Identification

Unique Protocol Identification Number
NCT05586646
Brief Title
Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients
Official Title
Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2022 (Actual)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Air Force Specialized Hospital, Cairo, Egypt

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In this clinical trial, we will assess pressure ulcer healing rates in critically ill patients supplemented with IV Alanyl-Glutamine in comparison with critically ill patients not supplemented with alanyl-glutamine.
Detailed Description
This clinical trial will include 200 Egyptian Critically ill patients with bed sores equal or more than grade II selected from ward or ICU at Air Force specialized Hospital. They will be classified into 2 groups: Group I: 100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration). Group II: 100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pressure Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This clinical trial will include 200 Egyptian Critically ill patients with bed sores equal or more than grade II selected from ward or ICU at Air Force specialized Hospital. They will be classified into 2 groups: Group I: 100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration). Group II: 100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
control group
Arm Type
No Intervention
Arm Description
100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations
Arm Title
alanyl-glutamine group
Arm Type
Experimental
Arm Description
100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration).
Intervention Type
Dietary Supplement
Intervention Name(s)
alanyl-glutamine
Other Intervention Name(s)
Dipeptiven
Intervention Description
Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
Primary Outcome Measure Information:
Title
Percentage change in pressure ulcer length
Description
Final ulcer length/original ulcer length x 100
Time Frame
2 weeks
Title
Percentage change in pressure ulcer depth
Description
Final ulcer depth/original ulcer depth x 100
Time Frame
2 weeks
Title
Percentage change in pressure ulcer area
Description
Final ulcer area/original ulcer area x 100
Time Frame
2 weeks
Title
Percentage change in proportion of viable wound tissue
Description
Final proportion of viable wound tissue /original proportion of viable wound tissue x 100
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with pressure ulcers stage 2,3 or 4, non-healing admitted to Air force specialized hospital for more than a week. Exclusion Criteria: Patients with renal impairment (GFR </= 30) Patients who require fluid restriction < 1 Litre/day. Patients with liver cirrhosis. (Child B and C) Length of stay< 2 weeks. Patients with deep tissue infection and/or requiring debridement of necrotic or sloughy tissue. Hemodynamically unstable patients. (On high dose of cardiac supports)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rana Hamed, Master
Phone
01002372975
Email
ranona48@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enas Mogawer, Professor
Organizational Affiliation
Air Force Specialized Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Air Force Specialized Hospital
City
Cairo
State/Province
New Cairo
Country
Egypt
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients

We'll reach out to this number within 24 hrs